Speakers & Panelists

2024 Invited and Confirmed Panelists

  • Michael Aberman, MD, General Partner, Regeneron Ventures
  • Peter Alff, PhD, Venture Partner, Orange Grove Bio
  • Troy André, PhD, SVP, Business Innovation, Lead, Commercial Strategy & Innovation, Pfizer, Inc.
  • Marc Appel, JD, MBA, Entrepreneur In Residence, Yale Ventures
  • Michael Baran, PhD, MBA, Partner, Pfizer Ventures, Executive Director, External Science & Innovation, Worldwide R&D, Pfizer, Inc.
  • Dawn Bell, PharmD, CEO, Antlia Bioscience, Founder & Director, Myracle Therapeutics, Board Member, NewYorkBIO
  • Michael R. Bielski, MS, Founder & President, DevTech Partners
  • Lazar Bojic, PhD, Head, Investor Network, Curie.Bio
  • Ava Bousher, DVM, PharmD, Global Access Strategy & Pricing, Senior Director, Oncology GU Pipeline & BD Lead, Pfizer
  • Scott P. Bruder, MD, PhD, Founder & CEO, Bruder Consulting & Venture Group
  • Brian Busser, PhD, Founder & SVP, R&D, Enceladus Bio
  • Adrian Charbin, PhD, Executive Director, Solid Tumor Strategy, Novartis
  • Eva Chmielnicki, PhD, Senior Director, Business Development, Bristol Myers Squibb
  • Pavan Choksi, Partner, Arkitekt Ventures
  • Silvia Garcia Codony, MBA, MSc, Assistant Vice President, NY Ventures, Empire State Development
  • J. Robert Coleman, PhD, CEO, Hervolution
  • Alexander Dundara, CPA, MBA, Partner, Life Sciences, Technology & Emerging Growth, Withum
  • Diane Fabel, PhD, Director, Operations, Center for Biotechnology 
  • Jonathan Fassberg, MBA, Managing Partner, Astr Partners
  • Christine Fischette, PhD, CEO, BioLinkUp
  • Sherry Grisewood, CFA, Senior Investment Officer, FoxHill Asset Management
  • Jiaping Gu, PhD, Investment Director & Partner, Takeda Ventures
  • Gaurav Gupta, MD, MSE, Co-Managing Partner, Life Science Private Capital, J.P. Morgan Private Capital
  • John Gustofson, MS, MBA, Head, Chugai Venture Fund
  • Harold Hess, Partner, EisnerAmper LLP
  • Poorya Hosseini, Partner, Camford Capital
  • Chun Hu, PhD, Associate, Canaan Partners
  • Matthew R. Kittay, MBA, Partner, Co-Chair of Mergers & Acquisitions, Fox Rothschild LLP
  • Ben Kromnick, Head of Healthcare and Life Sciences, Mercury
  • Orly Levitan, PhD, VP, Partnerships and Business Development, Pragma Bio
  • Sanford J. Madigan, PhD, Managing Partner, Avalon BioVentures
  • Jonathan Mandelbaum, PhD, Vice President, OrbiMed
  • Bridget Martell, MD, MA, Operating Partner, Biotechnology, Two Bear Capital
  • Megan McGill, MD, PhD, CEO, Epitor Therapeutics
  • Rachel Mears, Partner, Jeito Capital
  • Lawrence Monoson, MSc, Co-Founder, RxData, Inc.
  • Remo Moomiaie-Qajar, MD, Founder and CEO, Cytonus Therapeutics
  • Marian Nakada, PhD, VP, Venture Investments, Johnson & Johnson Innovation – JJDC
  • Saikat Nandi, PhD, MS, Founder & Managing Partner, Gene Allele Capital
  • Michael Norsen, MBA, Vice President, Alexandria Venture Investments & Head, LaunchLabs-NYC
  • Sandra Pérez Baos, PhD, Associate, 2048 Ventures
  • Maria Luisa Pineda, PhD, CEO, Envisagenics
  • John Prufeta, General Partner, Medical Excellence Capital, LLC
  • Clinton T. Rubin, PhD, Director, Center for Biotechnology
  • Uciane Scarlett, PhD, Principal, MPM Capital
  • Ryan Schipke, Director, Johnson & Johnson – Innovative Medicine, Business Development
  • Joel Sendek, Managing Director, Head of Healthcare Life Sciences Research, Oppenheimer & Co. Inc.
  • Gaurav Shah, MD, CEO, Rocket Pharma
  • Nimish Shah, MBA, MPH, Partner, Venrock
  • David Shin, MD, Venture Partner, BioAdvance
  • Nadim Shohdy, PhD, VP, Corporate Development, Hyku Bioscience
  • Yaniv Sneor, Co-Founder, Mid Atlantic Bio Angels; CEO, Native State Therapeutics
  • Isaac Stoner, MBA, Director, Co-Founder & CEO, Octagon Therapeutics
  • R. Nolan Townsend, MBA, CEO, Lexeo Therapeutics
  • Gerardo Ubaghs, CFO, Frontier Medicines
  • Pete Vaccaro, Partner, Formulary Insights
  • Xinchen Wang, PhD, Co-Founder & CEO, Waypoint Bio
  • Anton Xavier, MBA, Director, Startup Banking Life Sciences, SVB Financial Group
  • Adam Yaari, PhD, Co-Founder & CEO, Serinus.Bio
  • Cookie Yu, PhD, Investment Director, Samsung Ventures
  • Alex Zisson, Managing Director, H.I.G. Capital